Tweaking epigenetic machinery is
increasingly popular as a therapeutic strategy. Epigenetics often involves
modification to proteins – such as histones – that interact with DNA. One
common type of modification is methylation of lysine or arginine residues. A
couple months ago we highlighted how fragment-based approaches were used to
discover inhibitors of a methyltransferase, one of many classes of protein-modifying
enzymes that underlie epigenetics. Just as methyltransferases put methyl groups
on, demethylases take methyl groups off. In a recent paper in J. Med. Chem., Udo Oppermann, Brian
Shoichet, and Danica Fujimori and their collaborators at the University of
Oxford and UCSF show that demethylases too can be successfully targeted with
fragments. What’s more, the work exemplifies concrete contributions of
computational approaches to both identify and advance fragments.
The demethylase KDM4C has been
implicated in cancer. This enzyme uses iron, the cofactor α-ketoglutarate
(α-KG), and oxygen as part of its mechanism. The researchers ran a
computational screen (using DOCK 3.6) of more than 600,000 compounds in the
ZINC fragment library. Top-scoring hits were triaged on the basis of novelty
and good interactions with the iron atom, and 14 fragments were tested in a
functional assay. Remarkably, all of them were active, with 7 showing IC50
values < 200 µM!
Several of the top hits were
5-aminosalicylates such as compound 4. Testing 80 commercial analogs led to low
micromolar inhibitors, but these could not be further optimized. Moreover,
despite the small size and polarity of these compounds, many of them showed
signs of aggregation – a reminder that this type of artifact must always be
considered.
Unfortunately, crystallography was also not successful for any of the fragments or analogs. But the researchers noticed that, according to the docking results, fragments such as compound 4 could assume two different binding modes: in one, the carboxylate and phenol interacted with the iron atom, while in the other the carboxylate interacted with lysine and tyrosine residues in the protein. This inspired several ideas for fragment merging, leading to molecules such as compound 45. Additional variations led to mid-nanomolar inhibitors such as compound 35.
As expected, these molecules are
competitive with the α-KG cofactor (which normally binds to the iron atom) but
not with the peptide substrate. Many also showed encouraging selectivity
profiles against other demethylases, though no cell data are reported. Finally,
crystallography mostly confirmed the predicted binding models for several of
the merged compounds, including compound 35.
No comments:
Post a Comment